MR contrast agents

Applied Radiology

Volumn 35, Issue 1, 2006, Pages 18-27

  Kalva, Sanjeeva P ^a   Blake, Michael A ^a   Sahani, Dushyant V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADOCOLETIC ACID; GADODIAMIDE; GADOFLUORINE M; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOMELITOL; GADOMER 17; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; MANGAFODIPIR; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SHU 555C; SUPERPARAMAGNETIC IRON OXIDE; SUPRAVIST; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BILE DUCT OBSTRUCTION; BILE LEAKAGE; BURNING SENSATION; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIZZINESS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BINDING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SAFETY; DRUG SPECIFICITY; DRUG UPTAKE; EXTRACELLULAR SPACE; FLUSHING; HEADACHE; HUMAN; IMAGING SYSTEM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; RADIOSENSITIVITY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TASTE DISORDER;

EID: 31344459283     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging. 1999;10:477-484.
2. Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol. 2003;13:2688-2698.
3. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: Characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology. 1994;190:417-423.
4. Colosimo C, Manfredi R, Tartaglione T. Contrast enhancement issues in the MR evaluation of the central nervous system. Eur Radiol. 1997;7(suppl 5):231-237.
5. Prince MR. Gadolinium-enhanced MR aortography. Radiology. 1994;191:155-164.
6. Tanenbaum LN. MR contrast agents: Advanced power-injected applications. Appl Radiol. Aug 2001;30 (8) (suppl):20-25.
7. Toft KG, Hustvedt SO, Grant D, et al. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs. Eur J Drug Metab Pharmacokinet. 1997;22: 65-72.
8. Oudkerk M, Torres CG, Song B, et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: Multicenter study comparing MR and dual-phase spiral CT. Radiology. 2002;223:517-524.
9. Weissleder R. Liver MR imaging with iron oxides: Toward consensus and clinical practice. Radiology. 1994;193:593-595.
10. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology. 1996;200: 785-792.
11. Reimer P, Balzar T. Ferucarbotran. Ferucarbotran (Resovist): A new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: Properties, clinical development, and applications. Eur Radiol 2003;13:1266-1276.
12. Gerber BL, Bluemke DA, Chin BB, et al. Single-vessel coronary artery stenosis: Myocardial perfusion imaging with Gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine. Radiology. 2002;225: 104-112.
13. Daldrup-Link HE, Rydland J, Helbich TH, et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: Initial phase II multicenter trial. Radiology. 2003;229: 885-892.
14. Harisinghani MG, Barentsz J, Hahn PF, et al. Non-invasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348:2491-2499.
15. Misselwitz B, Platzek J, Raduchel B. Gadofluorine 8: Initial experience with a new contrast medium for interstitial MR lymphography. MAGMA. 1999;8:190-195.
16. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipedimic rabbits. Circulation. 2001;103:415-422.
17. Weinmann HJ, Barkhausen J, Heyer C, et al. Contrast enhanced MRI of atherosclerotic plaques by a novel gadolinium based agent. Presented at the Tenth ISMRM Scientific Meeting and Exhibition, Honolulu, HI, May 2002.
18. Choi SH, Lee SS, Choi SI, et al. Occlusive myocardial infarction: Investigation of bis-gadolinium mesoporphyrins-enhanced T1-weighted MR imaging in a cat model. Radiology. 2001;220:436-440.
19. Luciani A, Olivier JC, Clement O, et al. Glucose-receptor MR imaging of tumors: Study in mice with PEGylated paramagnetic niosomes. Radiology. 2004; 231:135-142.
20. Ni Y, Marchal G, Herijgers P, et al. Paramagnetic metalloporphyrins: From enhancers of malignant tumors to makers of myocardial infarcts. Acad Radiol. 1996;3(suppl 2):S395-397.
21. Yu X, Song SK, Chen J, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med. 2000;44:867-872.